Clinical Trial Update: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 1/Phase 2 study of ADI-PEG 20 in combination with gemcitabine and docetaxel for patients with non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non Small Cell Lung Cancer, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING